SEC Form 4 · accession 0001789617-26-000004
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Heerma
Officer — EVP, CHIEF COMMERCIAL OFFICER
Period of report
Sep 15, 2026
Accepted (ET)
Sep 17, 2026 · 9:35 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 15, 2026 | M | 39,283 | $26.88 | A | 181,349 | D | |
| Common Stock | Sep 15, 2026 | M | 1,381 | $22.40 | A | 182,730 | D | |
| Common Stock | Sep 15, 2026 | M | 36,526 | $8.93 | A | 219,256 | D | |
| Common StockF3 | Sep 15, 2026 | S | 71,938 | $62.0517 | D | 147,318 | D | |
| Common StockF4 | Sep 15, 2026 | S | 27,421 | $62.5936 | D | 119,897 | D | |
| Common StockF5 | Sep 15, 2026 | S | 1,400 | $63.6521 | D | 118,497 | D | |
| Common StockF6 | Sep 15, 2026 | S | 1,431 | $65.3093 | D | 117,066 | D | |
| Common Stock | Sep 16, 2026 | M | 100,000 | $11.25 | A | 217,066 | D | |
| Common Stock | Sep 16, 2026 | M | 55,000 | $15.46 | A | 272,066 | D | |
| Common Stock | Sep 16, 2026 | M | 17,717 | $26.88 | A | 289,783 | D | |
| Common StockF7 | Sep 16, 2026 | S | 93,604 | $63.2471 | D | 196,179 | D | |
| Common StockF8 | Sep 16, 2026 | S | 79,113 | $63.6546 | D | 117,066 | D | |
| Common Stock | Sep 17, 2026 | M | 8,282 | $22.40 | A | 125,348 | D | |
| Common StockF9 | Sep 17, 2026 | S | 8,282 | $65.0709 | D | 117,066 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee stock option (right to buy)F10 | $26.88 | Sep 15, 2026 | M | 39,283 | D | — | Jan 21, 2031 | Common Stock | 39,283 | 18,217 | D |
| Employee stock option (right to buy)F11 | $22.40 | Sep 15, 2026 | M | 1,381 | D | — | Jan 31, 2033 | Common Stock | 1,381 | 53,119 | D |
| Employee stock option (right to buy)F12 | $8.93 | Sep 15, 2026 | M | 36,526 | D | — | Jan 31, 2034 | Common Stock | 36,526 | 28,474 | D |
| Employee stock option (right to buy)F10 | $11.25 | Sep 16, 2026 | M | 100,000 | D | — | Oct 1, 2029 | Common Stock | 100,000 | 0 | D |
| Employee stock option (right to buy)F10 | $15.46 | Sep 16, 2026 | M | 55,000 | D | — | Jan 31, 2030 | Common Stock | 55,000 | 0 | D |
| Employee stock option (right to buy)F10 | $26.88 | Sep 16, 2026 | M | 17,717 | D | — | Jan 21, 2031 | Common Stock | 17,717 | 500 | D |
| Employee stock option (right to buy)F11 | $22.40 | Sep 17, 2026 | M | 8,282 | D | — | Jan 31, 2033 | Common Stock | 8,282 | 44,837 | D |
Explanation of responses
- F1Includes 1,382 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026.
- F10The stock option is fully vested and exercisable.
- F11One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.
- F12One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.
- F2This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- F3The weighted average sale price for the transaction reported was $62.0517, and the range of prices were between $61.43 and $62.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F4The weighted average sale price for the transaction reported was $62.5936, and the range of prices were between $62.43 and $63.27. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F5The weighted average sale price for the transaction reported was $63.6521, and the range of prices were between $63.56 and $63.75. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F6The weighted average sale price for the transaction reported was $65.3093, and the range of prices were between $65.30 and $65.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F7The weighted average sale price for the transaction reported was $63.2471, and the range of prices were between $62.50 and $63.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F8The weighted average sale price for the transaction reported was $63.6546, and the range of prices were between $63.50 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F9The weighted average sale price for the transaction reported was $65.0709, and the range of prices were between $65.00 and $65.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.